Rare rheumatology disease in spotlight after Sanofi, Regeneron nab first drug approval, more in pipeline potentials
Polymyalgia rheumatica (PMR) is a rare condition in older adults, most often women, that causes widespread muscle and joint pain. It’s difficult to diagnose — sometimes confused with rheumatoid arthritis (RA), lupus or fibromyalgia — and until recently didn’t have an approved treatment.
That changed when Sanofi and Regeneron’s anti IL-6 receptor drug Kevzara (sarilumab) earned FDA approval in February as a PMR treatment after corticosteroids fail. It’s already approved for moderate to severe RA after at least one other disease-modifying therapy fails to work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
